Wegovy (Semaglutide 2.4 mg) Nausea: When to Call the Doctor

How common is nausea on Wegovy 2.4 mg?

Wegovy 2.4 mg injection was studied in three randomized, double-blind, placebo-controlled trials that included 2,116 adults treated for up to 68 weeks and 1,261 adults on placebo [1]. In the pooled adverse-reaction table, nausea was reported by 44% of people on Wegovy and 16% on placebo. Vomiting was 24% versus 6%, diarrhea 30% versus 16%, constipation 24% versus 11%, and abdominal pain 20% versus 10% [1]. Any gastrointestinal reaction was reported by 73% versus 47% [1].

Most people who had nausea did not stop treatment for it. Permanent discontinuation for any adverse reaction occurred in 6.8% of Wegovy-treated adults versus 3.2% on placebo, and the most common reasons were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%) and diarrhea (0.7% versus 0.1%) [1]. The label separately lists severe gastrointestinal adverse reactions at 4.1% versus 0.9% on placebo [1].

Nausea was somewhat more common at the higher dose. In the two 72-week trials that tested 7.2 mg weekly, nausea was reported by 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo [1].

Wegovy is a GLP-1 receptor agonist, and the label notes that it delays gastric emptying [1]. The label lists nausea among the most common adverse reactions, at an incidence of 5% or more, in adults and in pediatric patients aged 12 and older [1].

Which symptoms does the label single out?

The label's warnings are about what nausea and vomiting can accompany, not about nausea by itself. These are the situations it describes.

Persistent or severe abdominal pain. The label says acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Wegovy. It says to watch for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and that if pancreatitis is suspected Wegovy should be discontinued and appropriate management started [1]. Acute pancreatitis was confirmed in 4 Wegovy-treated adults in the clinical trials (0.2 cases per 100 patient-years) versus 1 on placebo [1].

Signs of gallbladder disease. In the adult weight-reduction trials, cholelithiasis was reported by 1.6% of Wegovy-treated patients versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% [1]. The label says that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated. It adds that substantial or rapid weight loss can increase the risk of cholelithiasis, but acute gallbladder disease was still more frequent with Wegovy than placebo after accounting for the degree of weight loss [1].

Vomiting or diarrhea that causes fluid loss. The label warns about acute kidney injury from volume depletion and reports it at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, often after gastrointestinal fluid loss [1]. It says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1].

Severe gastrointestinal reactions. The label carries a warning for severe gastrointestinal adverse reactions and says Wegovy is not recommended in patients with severe gastroparesis [1]. Its postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction, and the label notes that frequency cannot be estimated from voluntary reports [1].

Swelling, hives or trouble breathing. Anaphylaxis and angioedema have been reported with Wegovy. The label says to discontinue Wegovy if a hypersensitivity reaction is suspected and to promptly seek medical advice [1]. A prior serious hypersensitivity reaction to semaglutide or an excipient is a contraindication [1].

Neck mass or trouble swallowing. Because semaglutide caused thyroid C-cell tumors in rodents, the boxed warning tells prescribers to counsel patients about a mass in the neck, trouble swallowing, shortness of breath and persistent hoarseness. Whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans is unknown [1].

What the label says about the dose when nausea is hard to manage

Wegovy is titrated upward: 0.25 mg weekly for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, then a maintenance dose from week 17 [1]. In adults the maintenance dose is 2.4 mg (recommended) or 1.7 mg, and adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go up to a maximum of 7.2 mg weekly [1]. The label says to follow the escalation schedule to reduce the risk of gastrointestinal adverse reactions, and that if a dose is not tolerated during escalation, consider delaying escalation for 4 weeks [1].

For a missed injection, the label says to administer it as soon as possible if the next scheduled dose is more than 2 days away, and not to administer it if the next dose is less than 2 days away. If 2 or more consecutive doses are missed, it says to reinitiate dosage escalation at a lower dosage [1].

How long does nausea last?

The label reports how many people had nausea across trials of up to 68 weeks, not how long an individual episode lasts, and we found no published figure for a typical duration. What the label does give is the drug's time course: the elimination half-life of semaglutide is about 1 week, and the drug stays in the body for about 5 to 7 weeks after the last 2.4 mg injection [1].